Quantcast

Industry news that matters to you.  Learn more

Big Pharma Joins NIH’s Cancer Moonshot for a Biomarker Hunt

Eleven drug companies are joining forces with the U.S. National Institutes of Health’s Cancer Moonshot to expedite the discovery of cancer immunotherapy biomarkers, molecular bar codes that help doctors know how to treat a tumor and gauge how well a person responds to a drug.

Sanguine’s Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research

Sanguine Biosciences – a biotechnology company focusing on technology development, patient engagement and study recruitment – will use its proprietary mobile application and direct-to-patient platform, called Sangre, to help Pfizer Inc. find and recruit people diagnosed with Congenital Insensitivity to Pain (CIP) and their family members to participate in voluntary research, which will be used to help potentially identify DNA mutations and hopefully aid in informing the development of potential therapies for chronic pain.

KineMed Collaboration with Pfizer Inc. in Diabetes is Extended

KineMed Inc. recently announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed’s novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

 

Groundbreaking Collaborative Clinical Trial Launched

A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial. 

Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimer’s Disease

Akili Interactive Labs Inc. (“Akili”) recently announced that it has entered into an agreement with Pfizer Inc. to test the ability of Akili’s mobile video game platform (“Project EVO”) to detect cognitive differences in healthy elderly people at risk of developing Alzheimer’s disease. To Akili’s knowledge this is the first time that a large pharmaceutical company will test the use of a mobile video game as a  clinical tool to determine early signs of neurodegenerative disease pathology.